Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051741 | 0.90 | MEN1 (0.50) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL21671263 | 0.87 | MEN1 (0.56) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL25002073 | 0.86 | MEN1 (0.54) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19042827 | 0.86 | MEN1 (0.58) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL25863651 | 0.84 | AAK1 (0.56) | LTA4H | |
| SCHEMBL18268264 | 0.83 | MEN1 (0.52) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL21862103 | 0.82 | MEN1 (0.60) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL16252543 | 0.82 | KMT2A (0.57) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL22394067 | 0.82 | MEN1 (0.53) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL24252193 | 0.81 | SMN1; SMN2 (0.51) | MEN1KMT2AMAPTLTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-9902740-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | THE SCRIPPS RESEARCH INSTITUTE | 2018-02-22 | — | — | US | disclosed |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822112-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822144-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140047-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR9 | MEN1 4020/4885KMT2A 2617/4885CA12 4864/4885 |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | MEN1 1678/4885KMT2A 934/4885CA12 829/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | MEN1 1468/4885KMT2A 1718/4885CA12 703/4885 |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | CD22, GDI2, GDI1 | MEN1 3919/4885KMT2A 2345/4885CA12 323/4885 |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | MEN1 1253/4885KMT2A 874/4885CA12 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.